Michael Barbella, Managing Editor03.28.23
Vitrolife AB has appointed Bronwyn Brophy is appointed as its new CEO, replacing Thomas Axelsson.
Brophy has extensive experience in the global life sciences and medtech arenas, having worked for Thermo Fisher Scientific, Medtronic plc, and Johnson & Johnson. In her last years with Thermo Fischer, Brophy was heading the Immunodiagnostics Division globally and before that served as president of the EMEA region.
“I am very pleased that we have been able to assign Bronwyn Brophy as CEO," Board Chairman Jón Sigurdsson said. "She has an extensive experience of developing businesses and has a wide international experience which is important for Vitrolife. I would like to thank Thomas Axelsson for an excellent job done for Vitrolife and for our great cooperation.”
Bronwyn Brophy will join the company by Aug. 1.
Axelsson is leaving the company on March 31. Board Chairman Jón Sigurdsson will lead the company until Brophy begins her appointment. Consequently, the Board of Directors has appointed Henrik Blomquist as chairman until the annual general meeting on April 27.
“I am very honored to the appointment as new CEO of Vitrolife. I believe the company has a very exciting future with great growth potential with strong distributors and global partners,” Brophy stated.
Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, the company develops services and products for personalized genetic information and medical devices. Headquartered in Gothenburg, Sweden, Vitrolife Group employs 1,100 people worldwide. Vitrolife Group’s products and services are available in more than 110 countries, through its own presence in 30 countries and a network of distributors.
Brophy has extensive experience in the global life sciences and medtech arenas, having worked for Thermo Fisher Scientific, Medtronic plc, and Johnson & Johnson. In her last years with Thermo Fischer, Brophy was heading the Immunodiagnostics Division globally and before that served as president of the EMEA region.
“I am very pleased that we have been able to assign Bronwyn Brophy as CEO," Board Chairman Jón Sigurdsson said. "She has an extensive experience of developing businesses and has a wide international experience which is important for Vitrolife. I would like to thank Thomas Axelsson for an excellent job done for Vitrolife and for our great cooperation.”
Bronwyn Brophy will join the company by Aug. 1.
Axelsson is leaving the company on March 31. Board Chairman Jón Sigurdsson will lead the company until Brophy begins her appointment. Consequently, the Board of Directors has appointed Henrik Blomquist as chairman until the annual general meeting on April 27.
“I am very honored to the appointment as new CEO of Vitrolife. I believe the company has a very exciting future with great growth potential with strong distributors and global partners,” Brophy stated.
Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, the company develops services and products for personalized genetic information and medical devices. Headquartered in Gothenburg, Sweden, Vitrolife Group employs 1,100 people worldwide. Vitrolife Group’s products and services are available in more than 110 countries, through its own presence in 30 countries and a network of distributors.